The FDA popular amivantamab-vmjw (Rybrevant) on Friday because the major treatment for patients with non-diminutive cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. Amivantamab is a bispecific antibody that targets EGFR and mesenchymal-epithelial transition part pathways. EGFR exon…